RxDoctor Payments Data

Harry Grossman, MD

Ophthalmology · Marlton, NJNPI 1043309487

Payments from drug & device makers

$1,927in general payments, 2019–2025

Across 89 payments — averaging $21.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • Sight Sciences, Inc.$213
  • Johnson & Johnson Surgical Vision, Inc.$209
  • Sun Pharmaceutical Industries Inc.$103
  • Bausch & Lomb Americas Inc.$65
  • Carl Zeiss Meditec, Inc.$65
  • plus $261 from 10 others

What the payments were for

  • Food & beverage$1,90999%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,927 in reported general payments places this provider in the 55th percentile of 583 ophthalmology providers in New Jersey.

See all ophthalmology providers in New Jersey

Medicare billing

Part B allowed, 2024
$419,492
Medicare patients
1,090
Services billed
3,134

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine70$100,249
XiidraLifitegrast55$83,446
RocklatanNetarsudil Mesylat/Latanoprost87$57,038
LumiganBimatoprost102$55,932
VyzultaLatanoprostene Bunod72$51,101
Cyclosporine39$28,126
MieboPerfluorohexyloctane/Pf17$22,655
CombiganBrimonidine Tartrate/Timolol44$19,520
Travoprost99$19,465
RhopressaNetarsudil Mesylate31$17,701
SimbrinzaBrinzolamide/Brimonidine Tart51$15,956
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol32$12,027
Brimonidine Tartrate144$11,553
Latanoprost681$8,905
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat284$5,962

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$54$175,701216 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo$65$157,202144 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$13$74,740118 claims
AlconSimbrinza$1,012$15,95651 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 583 ophthalmology providers in New Jersey.

Other ophthalmology in Marlton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →